Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | PTGES | O14684 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | CTSV | O60911 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 2/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1981976 | 0.85 | DYRK1A (0.41) | KMT2AMEN1ALDH1A1LMNANPC1 | |
| SCHEMBL17008483 | 0.85 | KMT2A (0.46) | KMT2AMEN1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL31086622 | 0.85 | KMT2A (0.46) | KMT2AMEN1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL31086675 | 0.85 | DYRK1A (0.41) | KMT2AMEN1ALDH1A1LMNANPC1 | |
| Hydrochloric Acid SCHEMBL28934123 | 0.84 | NPC1 (0.51) | KMT2AMEN1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL2472026 | 0.81 | CTSV (0.41) | KMT2AMEN1ALDH1A1LMNANPC1 | |
| SCHEMBL17014132 | 0.80 | MRGPRX4 (0.42) | KMT2AMEN1SMN1; SMN2MAPTMRGPRX4 | |
| SCHEMBL14842371 | 0.80 | POLB (0.53) | KMT2AMEN1SMN1; SMN2LMNANPC1 | |
| SCHEMBL31086760 | 0.79 | PTGES (0.38) | KMT2AMEN1ALDH1A1LMNANPC1 | |
| SCHEMBL17008491 | 0.78 | LMNA (0.40) | KMT2AMEN1SMN1; SMN2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118719-A1 | PYRAZOLYL UREAS AS KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2018-05-03 | — | — | US | disclosed |
| US-9884845-B2 | Pyrazolyl-ureas as kinase inhibitors | RESPIVERT LIMITED (GB) | 2018-02-06 | — | — | US | disclosed |
| US-20170182039-A1 | INHIBITOR OF p38 MAP KINASE | TOPIVERT PHARMA LTD. (GB) | 2017-06-29 | — | — | US | disclosed |
| US-9624196-B2 | Inhibitor of p38 MAP kinase | RESPIVERT LTD. (GB) | 2017-04-18 | — | — | US | disclosed |
| US-20170057945-A1 | NOVEL COMPOUNDS | RESPIVERT LIMITED (GB) | 2017-03-02 | — | — | US | disclosed |
| US-20160368896-A1 | INHIBITOR OF p38 MAP KINASE | RESPIVERT LIMITED (GB) | 2016-12-22 | — | — | US | disclosed |
| US-9447076-B2 | Inhibitor of p38 map kinase | RESPIVERT LTD. (GB) | 2016-09-20 | — | — | US | disclosed |
| US-20150232450-A1 | INHIBITOR OF p38 MAP KINASE | RESPIVERT LIMITED (GB) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118719-A1 | PYRAZOLYL UREAS AS KINASE INHIBITORS | MAP3K1, MAPK1, MAP3K7 | KMT2A 3644/4885MEN1 4747/4885SMN1; SMN2 4462/4885 |
| US-20170182039-A1 | INHIBITOR OF p38 MAP KINASE | MAPK1, MAPKAPK2, MAP3K1 | KMT2A 3285/4885MEN1 4673/4885SMN1; SMN2 2249/4885 |
| US-20160368896-A1 | INHIBITOR OF p38 MAP KINASE | MAPK1, MAPK4, MAPK8 | KMT2A 1987/4885MEN1 4410/4885SMN1; SMN2 1838/4885 |
| US-20170057945-A1 | NOVEL COMPOUNDS | MAPK1, MAPK6, MAPKAPK2 | KMT2A 4499/4885MEN1 4553/4885SMN1; SMN2 3106/4885 |
| US-20150232450-A1 | INHIBITOR OF p38 MAP KINASE | MAPK1, MAPKAPK2, MAPK10 | KMT2A 2821/4885MEN1 4243/4885SMN1; SMN2 1898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.